184 related articles for article (PubMed ID: 30370392)
1. Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy.
Kostadinova L; Shive CL; Zebrowski E; Fuller B; Rife K; Hirsch A; Compan A; Moreland A; Falck-Ytter Y; Popkin DL; Anthony DD
Pathog Immun; 2018 Sep; 3(1):149-163. PubMed ID: 30370392
[TBL] [Abstract][Full Text] [Related]
2. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.
Kostadinova L; Shive CL; Judge C; Zebrowski E; Compan A; Rife K; Hirsch A; Falck-Ytter Y; Schlatzer DM; Li X; Chance MR; Rodriguez B; Popkin DL; Anthony DD
J Infect Dis; 2016 Nov; 214(9):1438-1448. PubMed ID: 27540113
[TBL] [Abstract][Full Text] [Related]
3. Transient elastography score is elevated during rheumatoid factor-positive chronic hepatitis C virus infection and rheumatoid factor decline is highly variable over the course of direct-acting antiviral therapy.
Auma AWN; Kowal C; Shive CL; Lange A; Damjanovska S; Zebrowski E; Reyes E; Calabrese L; Kostadinova L; Falck-Ytter Y; Mattar M; Anthony DD
PLoS One; 2022; 17(4):e0267512. PubMed ID: 35482664
[TBL] [Abstract][Full Text] [Related]
4. Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.
Mascia C; Vita S; Zuccalà P; Marocco R; Tieghi T; Savinelli S; Rossi R; Iannetta M; Pozzetto I; Furlan C; Mengoni F; Mastroianni CM; Vullo V; Lichtner M
PLoS One; 2017; 12(6):e0179400. PubMed ID: 28636655
[TBL] [Abstract][Full Text] [Related]
5. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization.
Huynh T; Zhang J; Hu KQ
J Clin Transl Hepatol; 2018 Sep; 6(3):258-263. PubMed ID: 30271737
[No Abstract] [Full Text] [Related]
7. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.
Ferreira J; Bicho M; Serejo F
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543737
[TBL] [Abstract][Full Text] [Related]
8. The Roles of Fibrosis Index Based on Four Factors and Aspartate Transaminase-to-Platelet Ratio Index Scoring Systems as an Alternative to Transient Elastography Liver Stiffness in Liver Fibrosis Staging in Human Immunodeficiency Virus and Hepatitis C Virus Co-Infected Patients.
Ajao S; Roach D; Chan KH; Thimmanagari K; Muhanna A; Mutyala M; Lakasanni S; Slim J
Gastroenterology Res; 2021 Aug; 14(4):209-213. PubMed ID: 34527089
[TBL] [Abstract][Full Text] [Related]
9. Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women.
French AL; Grennan D; Daubert E; Seaberg EC; Peters M; Augenbraun M; Fischl M; Kassaye S; Franco R; Kuniholm M; Adimora AA; Workowski K; Weber KM
AIDS; 2021 Jul; 35(9):1433-1438. PubMed ID: 33710024
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.
Knop V; Mauss S; Goeser T; Geier A; Zimmermann T; Herzer K; Postel N; Friedrich-Rust M; Hofmann WP;
J Viral Hepat; 2020 Jul; 27(7):690-698. PubMed ID: 32096310
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C-An Experience from a Tertiary Care Hospital.
Taneja S; Tohra S; Duseja A; Dhiman RK; Chawla YK
J Clin Exp Hepatol; 2016 Dec; 6(4):282-290. PubMed ID: 28003717
[TBL] [Abstract][Full Text] [Related]
12. Systemic inflammation and liver damage in HIV/hepatitis C virus coinfection.
Shmagel KV; Saidakova EV; Shmagel NG; Korolevskaya LB; Chereshnev VA; Robinson J; Grivel JC; Douek DC; Margolis L; Anthony DD; Lederman MM
HIV Med; 2016 Sep; 17(8):581-9. PubMed ID: 27187749
[TBL] [Abstract][Full Text] [Related]
13. Endotoxemia Associated with Liver Disease Correlates with Systemic Inflammation and T Cell Exhaustion in Hepatitis C Virus Infection.
Shive CL; Kowal CM; Desotelle AF; Nguyen Y; Carbone S; Kostadinova L; Davitkov P; O'Mara M; Reihs A; Siddiqui H; Wilson BM; Anthony DD
Cells; 2023 Aug; 12(16):. PubMed ID: 37626844
[TBL] [Abstract][Full Text] [Related]
14. Changes in Serum Interferon Gamma and Interleukin-10 in Relation to Direct-Acting Antiviral Therapy of Chronic Hepatitis C Genotype 4: A Pilot Study.
Nabeel MM; Darwish RK; Alakel W; Maher R; Mostafa H; Hashem A; Elbeshlawy M; Abul-Fotouh A; Shousha HI; Saeed Marie M
J Clin Exp Hepatol; 2022; 12(2):428-434. PubMed ID: 35535108
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.
Parisi SG; Andreis S; Mengoli C; Menegotto N; Cavinato S; Scaggiante R; Andreoni M; Palù G; Basso M; Cattelan AM
Med Microbiol Immunol; 2018 Aug; 207(3-4):183-194. PubMed ID: 29523966
[TBL] [Abstract][Full Text] [Related]
16. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
Lund Laursen T; Brøckner Siggard C; Kazankov K; Damgaard Sandahl T; Møller HJ; Ong A; Douglas MW; George J; Tarp B; Hagelskjaer Kristensen L; Lund Laursen A; Hiramatsu A; Nakahara T; Chayama K; Grønbaek H
Scand J Gastroenterol; 2018 Aug; 53(8):986-993. PubMed ID: 29987961
[TBL] [Abstract][Full Text] [Related]
17. HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB-4 scores.
Huynh T; Ma S; Hu KQ
Hepatol Commun; 2022 Dec; 6(12):3496-3504. PubMed ID: 36221305
[TBL] [Abstract][Full Text] [Related]
18. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
Laguno M; Martínez-Rebollar M; Casanova M; de Lazzari E; González-Cordón A; Torres B; Inciarte A; Mora L; Ugarte A; Ambrosioni J; Blanco JL; Martínez E; Mallolas J
Clin Microbiol Infect; 2022 Apr; 28(4):610.e1-610.e7. PubMed ID: 34464735
[TBL] [Abstract][Full Text] [Related]
19. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.
Malin JJ; Boesecke C; Schwarze-Zander C; Wasmuth JC; Schlabe S; Trebicka J; Spengler U; Llibre JM; Jou T; Vasylyev M; Clotet B; Rockstroh JK
HIV Med; 2019 Mar; 20(3):230-236. PubMed ID: 30687989
[TBL] [Abstract][Full Text] [Related]
20. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
